The Innovative Health Initiative (IHI) Governing Board has appointed Niklas Blomberg to be the next Executive Director of the organisation. Dr Blomberg has extensive experience of working in Europe’s life science sector, and is currently Director of ELIXIR, the European life sciences data infrastructure. He will take up his duties at IHI in early 2024.

Six years after the first approved cell and gene therapy, the field is living a renaissance. 5 additional FDA-approved therapies were added in 2022 and could be doubled in 2023, setting a new pace to cell & gene therapies. The BioRN Annual Conference on September 29th in Heidelberg will highlight next-generation approaches in the field.

Six years after the first approved cell and gene therapy, the field is living a renaissance. 5 additional FDA-approved therapies were added in 2022 and could be doubled in 2023, setting a new pace to cell & gene therapies. The BioRN Annual Conference on September 29th in Heidelberg will highlight next-generation approaches in the field.

Carthera, a Sorbonne spin-off and developer of an innovative ultrasound-based medical device for the treatment of a wide range of brain disorders, today announced the successful completion of its €37.5m ($40m) Series B financing round.

Donaldson Company, Inc. (NYSE: DCI), a heritage provider of innovative filtration products and solutions, announced the acquisition of Univercells Technologies (Belgium), a global provider of innovative biomanufacturing solutions for cell and gene therapy research, development and commercial manufacturing.

Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting Claudin-1 (CLDN1). The molecule is significantly involved in the “tight junction” between cells. Now the company closed a three digit million Seriec C round.

From bacteria to cellulose fibers and lab grown paper. A greek project paves the way to save trees.

French AI-powered radiography diagnostics specialist Gleamer SAS has raises €27m in Series B round to expand its portfolio and accelerate its expansion.

Exosomes are extracellular vesicles ranging from 30 to 150 nm in diameter that are released from various types of cells, including tumor cells. They can induce apoptosis, modulate the immune system, and function as biomarkers for diagnosis. In addition, as an important component of cell-to-cell communication, exosomes can regulate the tumor microenvironment and are involved in the development, progression, and metastasis processes of numerous cancers1,2.

Multi-omics diagnostics specialist Centogene NV has received €30m to form a joint venture with PIF-owned pharmaceutical company Lifera in Saudi-Arabia.